X
Xiao-Dong Zhu
Researcher at Fudan University
Publications - 166
Citations - 5158
Xiao-Dong Zhu is an academic researcher from Fudan University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 27, co-authored 129 publications receiving 3734 citations. Previous affiliations of Xiao-Dong Zhu include Fudan University Shanghai Medical College & Chinese Ministry of Education.
Papers
More filters
Journal ArticleDOI
Prognostic significance of wait time for radical radiotherapy in locoregionally advanced nasopharyngeal carcinoma
TL;DR: The prognostic significance of wait time between definite diagnosis and initial radical radiotherapy is not well established in patients with locoregionally advanced nasopharyngeal carcinoma receiving both induction chemotherapy (IC) and concurrent chemoradiotherapy (CCRT).
Journal ArticleDOI
A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer
Xin Liu,Weijian Guo,Wen Zhang,Jiliang Yin,Jun Zhang,Xiao-Dong Zhu,Tianshu Liu,Zhiyu Chen,Biyun Wang,Jianhua Chang,Fangfang Lv,Xiaonan Hong,Huijie Wang,Jialei Wang,Xinmin Zhao,Xianghua Wu,Jin Li +16 more
TL;DR: Combination therapy comprising cetuximab and mFOLFIRI was well tolerated and active as a second-line treatment for patients with metastatic gastric cancer and potential biomarkers of clinical outcomes were identified.
Journal ArticleDOI
Genetic variant rs4072037 of MUC1 and gastric cancer risk in an Eastern Chinese population
Li Xin Qiu,Rui-Xi Hua,Lei Cheng,Jing He,Mengyun Wang,Fei Zhou,Xiao-Dong Zhu,Meng Hong Sun,Xiao Yan Zhou,Jin Li,Ya Nong Wang,Yajun Yang,Jiucun Wang,Li Jin,Wei Jian Guo,Qingyi Wei,Qingyi Wei +16 more
TL;DR: It is suggested that the MUC1 rs4072037G allele may be a low-penetrating protection factor for GCa risk in Chinese populations.
Journal ArticleDOI
Intra-tumoral heterogeneity and immune responses predicts prognosis of gastric cancer.
TL;DR: Low/intermediate MATH scores predicted longer OS, when compared to those with high MATH Score, and the immune response was obviously upregulated in patients with GC and low/inter intermediate MATH Scores.
Journal ArticleDOI
Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study).
TL;DR: This multicenter, nonrandomized phase II study was launched to evaluate the efficacy and safety of cetuximab in combination with modified FOLFIRI as second-line treatment for advanced gastric cancer patients.